Bristol-Myers Squibb Company
Bristol-Myers Squibb is an American pharmaceutical company specializing in the discovery, development, and commercialization of drugs for various therapeutic areas.
Price history of Bristol-Myers Squibb Company
Price history of Bristol-Myers Squibb Company
Performance & Momentum
Bristol-Myers Bolsters Oncology Pipeline with AI, Partnerships
Bristol-Myers Squibb (BMY) recently announced strategic collaborations, including a partnership with Microsoft to leverage artificial intelligence for early lung cancer detection and an alliance with Janux Therapeutics to develop treatments targeting solid tumors. These efforts aim to expand its digital health capabilities and strengthen its oncology position, a key sector for the company. Additionally, Citi raised its price target to $60 while maintaining a neutral rating, reflecting a positive sector outlook and optimistic forecasts for 2026.
Strategic Analysis
Bristol-Myers Squibb Company • 2026
Bristol-Myers Squibb is a major U.S. pharmaceutical group whose business is built on the discovery, development, and commercialization of high-value treatments, with a strong presence in oncology. Its positioning rests on recognized research expertise and a drug portfolio that combines therapeutic innovations with more mature revenue drivers.
- Exposure to attractive therapeutic areas, particularly oncology
- Sustained research and development capabilities supported by a large pharmaceutical platform
- Relative defensive profile of the healthcare sector, with revenues generally less cyclical than in other industries
- Dependence on portfolio replenishment to offset erosion in some mature products
- Sometimes uneven visibility on long-term growth amid competitive pressure and innovation cycles
- A more uneven share price history than some of its major pharmaceutical peers
Momentum has turned constructive again and reflects a clear improvement in market perception, with recent favorable performance after a more uneven period. Strategically, this suggests renewed investor interest in the stock, likely linked to the group’s ability to secure its revenue outlook and monetize its pipeline, even if the trend still needs to be confirmed over time.
Similar stocks to Bristol-Myers Squibb Company
Recent News
Bristol-Myers Squibb Company
UBS Raises Bristol-Myers Squibb Price Target to $65
3 months agoBristol-Myers Squibb (Bristol-Myers Squibb Company) is benefiting from renewed optimism in the biotech and pharma sectors. UBS upgraded its rating to "Buy," increasing its price target from $46 to $65, highlighting a positive sector turnaround. Additionally, Leerink maintains an "Outperform" rating with a $60 target, relying on multiple clinical results expected in 2026, which strengthens the stock’s growth outlook. Despite a recent slight pullback, strong institutional investor interest indicates heightened sensitivity to the stock price but also underscores confidence in the company’s long-term potential.
FDA Approves Breyanzi, First CAR T for Rare Lymphoma
4 months agoThe FDA's recent approval of Breyanzi, the first CAR T therapy for marginal zone lymphoma, represents a major breakthrough for Bristol-Myers Squibb. This decision is accompanied by a price target upgrade from Goldman Sachs, boosting optimism about the company's long-term growth potential. Despite a slight 0.7% decline, the market remains generally confident in the positive impact of this therapeutic innovation.
Bristol Myers Expands Alzheimer Trial, Shares Rise
5 months agoOn December 3, 2025, Bristol Myers announced an expansion in patient recruitment for its Alzheimer’s clinical trial, driving a notable 3.7% rise in its stock before market open. This increase reflects strong investor optimism about potential treatment advances, despite a current mild daily dip of -1.89%, which remains moderate compared to the recent positive momentum.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
